Combination therapy of lymphoma
AssigneeThe Trustees of Columbia University in the City of New York
InventorsJennifer Effie AMENGUAL, Jennifer LUE, Owen A. O'CONNOR
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for methods and compositions for treating cancer. A subject having lymphoma is administered an EZH2 inhibitor and an HDAC inhibitor. The combination of the EZH2 inhibitor and the HDAC inhibitor produces a synergistic effect on the cancer compared to the effect of the EZH2 inhibitor or the HDAC inhibitor alone.
Claims42
A method of treating lymphoma in a subject, comprising administering an EZH2 inhibitor and an HDAC inhibitor to the subject.
A method of treating lymphoma cells, comprising contacting the lymphoma cells with an EZH2 inhibitor and an HDAC inhibitor.
A method of treating lymphoma in a subject, comprising administering to the subject a BCL2 inhibitor, an EZH2 inhibitor, and an HDAC inhibitor.
A pharmaceutical composition comprising a first amount of an EZH2 inhibitor and a second amount of an HDAC inhibitor.
Dependencies are inferred from the claim text.